Literature DB >> 15327026

The therapeutic value of cannabinoids in MS: real or imaginary?

Joep Killestein, Chris Polman.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15327026     DOI： 10.1191/1352458504ms1064ed

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  4 in total

Review 1.  Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.

Authors:  Uwe K Zettl; Paulus Rommer; Petra Hipp; Robert Patejdl
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

2.  Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis.

Authors:  Rüdiger Birke; Stefanie Meister; Alexander Winkelmann; Burkhard Hinz; Udo I Walther
Journal:  J Clin Med       Date:  2022-06-27       Impact factor: 4.964

3.  New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids.

Authors:  Paul F Smith
Journal:  Ther Clin Risk Manag       Date:  2010-03-03       Impact factor: 2.423

Review 4.  "The Two Sides of the Same Coin"-Medical Cannabis, Cannabinoids and Immunity: Pros and Cons Explained.

Authors:  Mona Khoury; Idan Cohen; Gil Bar-Sela
Journal:  Pharmaceutics       Date:  2022-02-10       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.